Martinha Henrique

Correction: Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel

Pedro Mendes‐Bastos, Inês Lobo, Gilberto Pires da Rosa, Rita Pimenta et autres

pt (code pays fourni par la source)

Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel

Pedro Mendes-Bastos, Inês Lobo, Gilberto Pires da Rosa, Rita Pimenta et autres

OBJECTIVE: Chronic prurigo (CPG) is a chronic neuroinflammatory skin disease characterized by persistent itch, repeated scratching, and the presence of multiple skin lesions. CPG is a highly burdensome disease that significantly impairs patients' quality of life. The objective of these consensus recommendations …

pt (code pays fourni par la source)

Patient Satisfaction Using Guselkumab Self-administered Using the One-Press Device for Treatment of Moderate-to-Severe Psoriasis: Results from a National, Prospective, Real-World Study in Portugal (CERES Study)

Tiago Torres, João Teles Sousa, Joana Antunes, Pedro Mendes-Bastos et autres

INTRODUCTION: Guselkumab, a selective p19 subunit-targeted IL-23 inhibitor, has shown high efficacy and a favorable safety profile in clinical trials of moderate-to-severe plaque psoriasis (PsO). However, real-world data on patient satisfaction with the guselkumab One-Press device, particularly in Portuguese clinical practice, are …

pt, us (code pays fourni par la source)

Real‐World Effectiveness, Safety and Drug Survival of Tildrakizumab in Adult Patients With Plaque Psoriasis: A 2‐Year Portuguese Multicenter Retrospective Cohort Study

Tiago Torres, Bárbara Vieira Granja, Rita Venina de Amaral Pereira Guedes, Joana Antunes et autres

The data that supports the findings of this article is available from the corresponding author upon reasonable request.

pt (code pays fourni par la source)

Cutaneous non-volar melanoma dermoscopy and histopathology correlation: a systematic review protocol

Rita Bouceiro-Mendes, Martinha Henrique, Pedro Augusto-Simões

INTRODUCTION: Dermoscopy has a proved validity in the diagnosis of cutaneous melanoma, which is one of the most aggressive forms of skin cancer. Although some studies have demonstrated a relationship between specific dermoscopic and pathologic melanoma features, there is no solid evidence …

pt, it (code pays fourni par la source)

Update on Generalized Pustular Psoriasis

Tiago Torres, Joana Antunes, Rui Tavares Bello, Paulo Varela et autres

Generalized pustular psoriasis (GPP) is a rare but severe inflammatory skin disease characterized by the eruption of widespread sterile pustules, often accompanied by systemic inflammation. Although GPP can coexist with plaque psoriasis, it is increasingly recognized as a distinct entity with unique …

pt (code pays fourni par la source)

The APOLO Study: A Cross-Sectional Analysis of Disease Characteristics and Patient Burden in Moderate-to-Severe Atopic Dermatitis in Portugal

Bruno Kosa Lino Duarte, Pedro Mendes‐Bastos, Joana Antunes, Filomena Azevedo et autres

INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a substantial impact on patients' quality of life (QoL). This study aimed to characterize the burden of moderate-to-severe AD in the Portuguese population, focusing on patients' QoL and socioeconomic activities while …

pt (code pays fourni par la source)

CheckAP: Prevalence of Psoriatic Arthritis (PsA) and performance evaluation of the EARP Questionnaire in the population of Portuguese patients with Psoriasis followed in a dermatology setting

Ana Rita Henriques, Fernando Manuel Pimentel-Santos, João Sousa, Leandro Silva et autres

BACKGROUND: The percentage of Portuguese psoriasis patients with psoriatic arthritis is unknown but musculoskeletal complaints related to PsA affect up to a third of patients. Dermatologists can identify early PsA as skin symptoms often precede joint symptoms in 80% of patients. Efficient …

pt, es, us (code pays fourni par la source)

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study

Tiago Torres, Paulo Varela, Pedro Mendes‐Bastos, Sofia Magina et autres

Background: Real-world evidence plays a pivotal role in validating the efficacy of biologic drugs beyond the controlled environment of randomized trials.This study aimed to evaluate the effectiveness of tildrakizumab in treating moderate-to-severe psoriasis within a real-world setting over a 52-week period in …

pt (code pays fourni par la source)

A low level of health literacy is a predictor of corticophobia in atopic dermatitis

Tiago Fernandes Gomes, Katarína Kieselová, Victória Guiote, Martinha Henrique et autres

BACKGROUND: Topical corticosteroids (TCS) are the mainstay of treatment in atopic dermatitis (AD) flares. The fears and worries concerning TCS are known as corticophobia. Corticophobia is common in patients with AD and can lead to suboptimal TCS application and treatment failure. Health …

pt (code pays fourni par la source)

Persistence, effectiveness, and real‐world outcomes in psoriasis patients treated with secukinumab in Portugal

Pedro Mendes‐Bastos, Paulo Morais, Paulo Ferreira, Manuela Loureiro et autres

To characterize moderate to severe psoriasis (PsO) adult patients treated with secukinumab, estimate drug persistence and assess any reasons for treatment discontinuation. Non-interventional, retrospective, longitudinal record-based study including patients diagnosed with PsO who started secukinumab between January 2018 and January 2020. Baseline …

pt (code pays fourni par la source)

Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study

Tiago Torres, Maria João Paiva Lopes, Margarida Gonçalo, Cristina Claro et autres

INTRODUCTION: Atopic dermatitis (AD) is a difficult-to-treat inflammatory skin disease with a high impact on patients' quality of life. Dupilumab, an IL-4 and IL-13 inhibitor, was the first monoclonal antibody approved for the treatment of moderate-to-severe AD and is currently approved in …

pt, us (code pays fourni par la source)